The Alzheimer’s economy: is the new $56,000-a-year drug worth it?
US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
Full Article
The Alzheimer’s economy: is the new $56,000-a-year drug worth it?
FT.com
0 shares
1 views
You might like
Related news coverage
What universal healthcare should look like
Mashable
What universal healthcare should look like
The struggle to cover every American may continue for decades — and we need..
-
Alzheimer's drug stirs hope for patients, worry for doctors
SeattlePI.com
-
Stocks end mixed but Nasdaq powers to another record close
Proactive Investors
-
US stocks mixed at mid-session as traders get cautious on risk
Proactive Investors
-
Wall Street rises at the opening bell
Proactive Investors
Advertisement
More coverage
FDA Approves Highly Debated Alzheimer’s Drug
Newsy
Watch VideoGovernment health officials on Monday approved the first new drug for Alzheimer's disease in nearly 20 years,..
Wall Street set to open higher as inflation fears ease
Proactive Investors